Nieuws

MPR19u
RSV Vaccine mResvia Approved for Adults Aged 18 to 59 at Increased Risk
For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.
Zacks Investment Research on MSN23u
EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...
STAT4d
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...
CIDRAP3d
Moderna receives expanded approval for RSV vaccine
The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease ...
IEX.nl7d
Amerikaanse FDA keurt RSV-antilichaam van Merck goed voor zuigelingen
De Amerikaanse Food and Drug Administration heeft maandag Merck's preventieve antilichaam goedgekeurd om zuigelingen tot één ...
FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...
IEX.nl7d
Amerikaanse FDA keurt RSV-antistof van Merck goed voor baby’s
De Amerikaanse Food and Drug Administration (FDA) heeft maandag toestemming gegeven voor Merck’s preventieve antistofinjectie ...
BioPharma Dive3d
Moderna wins FDA OK to widen use of RSV vaccine
The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...
US CDC Official in Charge of COVID, RSV Data Resigns Ahead of Vaccine Meeting
The scientist, Dr. Fiona Havers, told colleagues at the Centers for Disease Control and Prevention on Monday that she no ...
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...
The Manila Times9u
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- ...